theory clinical_65_2
imports Main

begin

typedecl entity
typedecl event

consts
  Akt :: "entity ⇒ bool"
  Activated :: "entity ⇒ bool"
  CellularFunctions :: "entity ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Survival :: "entity ⇒ bool"
  Mediates :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Including :: "entity ⇒ entity ⇒ bool"
  Alpelisib :: "entity ⇒ bool"
  KinaseInhibitor :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  BreastCancers :: "entity ⇒ bool"
  UsedIn :: "entity ⇒ entity ⇒ bool"
  Pathway :: "entity ⇒ bool"
  PI3KAKT :: "entity ⇒ bool"
  Activation :: "entity ⇒ bool"
  Target :: "event ⇒ bool"
  InvolvedIn :: "entity ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Mutations :: "entity ⇒ bool"
  In :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Fully activated Akt mediates numerous cellular functions including proliferation and survival. *)
axiomatization where
  explanation_1: "∃x y z e. Akt x ∧ Activated x ∧ CellularFunctions y ∧ Proliferation z ∧ Survival z ∧ Mediates e ∧ Agent e x ∧ Patient e y ∧ Including y z"

(* Explanation 2: Alpelisib is a kinase inhibitor used in the treatment of certain breast cancers. *)
axiomatization where
  explanation_2: "∀x y z. Alpelisib x ∧ KinaseInhibitor y ∧ Treatment z ∧ BreastCancers z ∧ UsedIn y z ⟶ KinaseInhibitor x"

(* Explanation 3: Kinase inhibitors can target the PI3K/AKT pathway, which is involved in cellular proliferation and survival, by inhibiting its activation. *)
axiomatization where
  explanation_3: "∃x y z e1 e2. KinaseInhibitor x ∧ Pathway y ∧ PI3KAKT y ∧ Proliferation z ∧ Survival z ∧ Activation y ∧ Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ InvolvedIn y z ∧ Inhibit e2 ∧ Agent e2 x ∧ Patient e2 y"

theorem hypothesis:
  assumes asm: "KinaseInhibitor x ∧ Mutations y ∧ Pathway z ∧ PI3KAKT z ∧ Proliferation y ∧ Survival y"
  (* Hypothesis: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)
  shows "∃x y z e1 e2. KinaseInhibitor x ∧ Mutations y ∧ Pathway z ∧ PI3KAKT z ∧ Proliferation y ∧ Survival y ∧ Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ In y z ∧ Inhibit e2 ∧ Agent e2 x ∧ Patient e2 y"
proof -
  (* From the premise, we have known information about the kinase inhibitor, mutations, and the PI3K/AKT pathway. *)
  from asm have "KinaseInhibitor x ∧ Mutations y ∧ Pathway z ∧ PI3KAKT z ∧ Proliferation y ∧ Survival y" by blast
  (* Explanation 3 provides that kinase inhibitors can target the PI3K/AKT pathway and inhibit its activation, which is involved in proliferation and survival. *)
  (* There is a logical relation Implies(E, F) and Implies(E, G) from explanation 3. *)
  (* We can infer that using a kinase inhibitor targets mutations in the PI3K/AKT pathway and inhibits proliferation and survival. *)
  then have "Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ In y z ∧ Inhibit e2 ∧ Agent e2 x ∧ Patient e2 y" sledgehammer
  then show ?thesis <ATP>
qed

end
